Mountain View, CA, United States
Mountain View, CA, United States
SEARCH FILTERS
Time filter
Source Type

Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C_(max)) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.


Patent
MAP Pharmaceuticals | Date: 2016-11-15

The present invention provides for an enhanced eductor element that significantly increases the amount of pressure generated at the siphon tube without significantly increasing the flow resistance through the eductor. The invention further provides for breath-actuated inhalation devices comprising the enhanced eductor element as an actuation mechanism.


Patent
MAP Pharmaceuticals | Date: 2015-08-28

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT_(1D )and/or the 5-HT_(1B )receptor, without agonizing the 5-HT_(2B )receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha_(2A )and/or the alpha_(2B )receptors using the compounds and compositions disclosed herein.


Patent
MAP Pharmaceuticals | Date: 2016-05-23

8-Hydroxy-Dihydroergotamine (8-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of migraine disorders using the compounds, compositions, dosage forms and administration techniques disclosed herein.


Patent
MAP Pharmaceuticals | Date: 2015-11-18

The present invention provides for an enhanced eductor element that significantly increases the amount of pressure generated at the siphon tube without significantly increasing the flow resistance through the eductor. The invention further provides for breath-actuated inhalation devices comprising the enhanced eductor element as an actuation mechanism.


Patent
MAP Pharmaceuticals | Date: 2015-11-17

A pulmonary drug delivery device having one or more vortexing elements which impart beneficial flow characteristics to an inspiratory air flow carrying a medicament into the patients lungs.


Patent
MAP Pharmaceuticals | Date: 2015-04-29

8-Hydroxy-Dihydroergotamine (8-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinsons disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.


Patent
MAP Pharmaceuticals | Date: 2016-09-22

A medicament dispenser, in particular a metered dose inhaler, which is able to count the number of time the dispenser is activated and then disable the device, which then prevents any additional medicament from being dispensed. Additional embodiments include a medicament dispenser which are adapted to display either the number of activations that have occurred or the number of activations remaining.


Patent
MAP Pharmaceuticals | Date: 2015-01-09

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT_(1D )and/or the 5-HT_(1B )receptor, without agonizing the 5-HT_(2B )receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha_(2A )and/or the alpha_(2B )receptors using the compounds and compositions disclosed herein.


Patent
MAP Pharmaceuticals | Date: 2015-03-27

Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinsons disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT_(2B )receptor and 5-HT_(2C )receptors the using the compounds and compositions disclosed herein.

Loading MAP Pharmaceuticals collaborators
Loading MAP Pharmaceuticals collaborators